文献速递临床试验与 GCP流行病学与生物统计

长期补充海洋源ω-3脂肪酸与安慰剂对抑郁风险或临床相关抑郁症状及情绪评分变化的影响:一项随机临床试验

Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

VITAL-DEP辅助研究纳入18353名无基线临床相关抑郁症状的50岁以上成人,随机接受海洋源ω-3脂肪酸(1 g/d鱼油,含465 mg二十碳五烯酸和375 mg二十二碳六烯酸)或安慰剂。中位随访5.3年,ω-3组抑郁或临床相关抑郁症状风险显著高于安慰剂组(HR 1.13,95%CI 1.01-1.26,P=0.03),但情绪评分变化无显著差异。结论不支持用ω-3补充剂预防成人抑郁。

要点

  • ω-3组抑郁或临床相关抑郁症状风险显著高于安慰剂组(HR 1.13,95%CI 1.01-1.26,P=0.03)。
  • ω-3组与安慰剂组PHQ-8评分变化均值差0.03分(95%CI -0.01至0.07,P=0.19),无显著差异。
  • 结论不支持在成人中使用ω-3补充剂预防抑郁。

核心结论

  • 在50岁及以上、基线无临床相关抑郁症状的成人中,与安慰剂相比,ω-3补充剂在小幅但统计学显著增加抑郁或临床相关抑郁症状风险方面结果不一,而情绪评分无差异,中位随访5.3年。
  • 这些发现不支持在成人中使用ω-3补充剂预防抑郁。

研究设计与样本

  • VITAL-DEP是VITAL随机试验的辅助研究,VITAL为在美国成人中进行的心血管疾病和癌症预防随机试验,共25871人。
  • VITAL-DEP共18353名成人参与,其中16657名有 incident 抑郁风险(无既往抑郁),1696名有复发性抑郁风险(既往抑郁但近2年无抑郁)。
  • 随机化时间为2011年11月至2014年3月,随机治疗于2017年12月31日结束。
  • 采用2×2析因设计随机分配至维生素D3(2000 IU/d)、海洋源ω-3脂肪酸(1 g/d鱼油,含465 mg二十碳五烯酸和375 mg二十二碳六烯酸)或安慰剂;9171人随机至ω-3组,9182人随机至匹配安慰剂组。

主要发现

  • 18353名随机参与者平均年龄67.5岁(SD 7.1),女性49.2%;90.3%完成试验(试验结束时存活者中93.5%完成);中位治疗时长5.3年。
  • ω-3与维生素D干预交互作用检验不显著(交互作用P=0.14)。
  • 抑郁风险比较:ω-3组651例事件(13.9/1000人年) vs 安慰剂组583例事件(12.3/1000人年),HR 1.13(95%CI 1.01-1.26),P=0.03,ω-3组风险显著高于安慰剂组。
  • 纵向情绪评分比较:ω-3组与安慰剂组PHQ-8评分变化均值差0.03分(95%CI -0.01至0.07),P=0.19,无显著差异。
  • 严重和常见不良事件发生率(ω-3组 vs 安慰剂组):主要心血管事件2.7% vs 2.9%,全因死亡3.3% vs 3.1%,自杀0.02% vs 0.01%,消化道出血2.6% vs 2.7%,容易瘀伤24.8% vs 25.1%,胃部不适或疼痛35.2% vs 35.1%。

临床怎么用

  • 原文结论指出,这些发现不支持在成人中使用ω-3补充剂预防抑郁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Marine omega-3 fatty acid (omega-3) supplements have been used to treat depression but their ability to prevent depression in the general adult population is unknown. OBJECTIVE: To test effects of omega-3 supplementation on late-life depression risk and mood scores. DESIGN, SETTING, AND PARTICIPANTS: A total of 18 353 adults participated in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized trial of cardiovascular disease and cancer prevention among 25 871 US adults. There were 16 657 at risk of incident depression (no previous depression) and 1696 at risk of recurrent depression (previous depression, but not for the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017. INTERVENTIONS: Randomized 2 × 2 factorial assignment to vitamin D3 (2000 IU/d), marine omega-3 fatty acids (1 g/d of fish oil, including 465 mg of eicosapentaenoic acid and 375 mg of docosahexaenoic acid) or placebo; 9171 were randomized to omega-3 and 9182 were randomized to matching placebo. MAIN OUTCOMES AND MEASURES: Prespecified coprimary outcomes were risk of depression or clinically relevant depressive symptoms (total of incident + recurrent cases); mean difference in mood score (8-item Patient Health Questionnaire [PHQ-8] depression scale). RESULTS: Among 18 353 participants who were randomized (mean age, 67.5 [SD, 7.1] years; 49.2% women), 90.3% completed the trial (93.5% among those alive at the end of the trial); the median treatment duration was 5.3 years. The test for interaction between the omega-3 and the vitamin D agents was not significant (P for interaction = .14). Depression risk was significantly higher comparing omega-3 (651 events, 13.9 per 1000 person-years) with placebo (583 events, 12.3 per 1000 person-years; hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P = .03). No significant differences were observed comparing omega-3 with placebo groups in longitudinal mood scores: the mean difference in change in PHQ-8 score was 0.03 points (95% CI, -0.01 to 0.07; P = .19). Regarding serious and common adverse events, the respective prevalence values in omega-3 vs placebo groups were major cardiovascular events (2.7% vs 2.9%), all-cause mortality (3.3% vs 3.1%), suicide (0.02% vs 0.01%), gastrointestinal bleeding (2.6% vs 2.7%), easy bruising (24.8% vs 25.1%), and stomach upset or pain (35.2% vs 35.1%). CONCLUSIONS AND RELEVANCE: Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with omega-3 supplements compared with placebo yielded mixed results, with a small but statistically significant increase in risk of depression or clinically relevant depressive symptoms but no difference in mood scores, over a median follow-up of 5.3 years. These findings do not support the use of omega-3 supplements in adults to prevent depression. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01696435 and NCT01169259.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Okereke OI, Vyas CM, Mischoulon D, et al. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2021. PMID: 34932079. doi:10.1001/jama.2021.21187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。